Juan Gabriel Álvarez Sánchez* and Ana Teresa Opina Pérez

Professor, Department of Gynecologists and Obstetricians Graduated from the University of Antioquia, Medellin, Colombia

*Corresponding Author: Juan Gabriel Álvarez Sánchez, Professor, Department of Gynecologists and Obstetricians Graduated from the University of Antioquia, Medellin, Colombia.

Received: July 01, 2022; Published: January 12, 2023

Abstract

Objective: The purpose of this study was to identify the possible association between blood eosinophilia and the diagnosis of ovarian cancer.

Methods: A retrospective cross-sectional study of phase 1 development of the diagnostic test was carried out. Data was collected from the medical records of patients who consulted at the San Vicente Foundation Hospital in the emergency department or medical appointment with a diagnosis of ovarian tumor. The patients with confirmed diagnosis of ovarian cancer were the cases and those without this diagnosis were the controls.

Results: 199 histories were analyzed; of which 99 were from patients diagnosed with ovarian cancer. Out of the total of patients with ovarian cancer; 11.1% presented blood eosinophilia vs. 6% of the control (P = 0.197). Regarding the stage of the disease; III was the one that presented the greatest association with 20% of the cases.

Conclusions: We hypothesized that the frequency of eosinophilia would be twice as high in women with ovarian cancer compared to women without it, which was found in our results, 11% vs. 6%. Although this difference did not show statistical significance for several reasons; we consider the possibility of designing a subsequent phase II study in order to observe the probability that patients with a positive test (eosinophilia in blood) have the disease (ovarian cancer).

Keywords: Ovarian Cancer; Diagnosis; Blood Eosinophilia

References

1. Barnholtz-Sloan JS., et al. “Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades”. American Journal of Obstetrics and Gynecology 189 (2003): 1120.
2. https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf
3. Symptoms - Foundation for Women’s Cancer (2017).
4. NCCN Clinical Practice Guidelines in Oncology (2017).
5. Zurawski VR., et al. “Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer”. International Journal of Cancer5 (1988): 677-680.
6. Shah CA., et al. “Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125”. Cancer Epidemiology, Biomarkers and Prevention 5 (2009): 1365-1372.
7. Sakkal S., et al. “Eosinophils in Cancer: Favourable or Unfavourable?” Current Medicinal Chemistry 7 (2016): 650-666.
8. Samoszuk M. “Eosinophils and human cancer”. Histology and Histopathology3 (1997): 807-812.
9. Van Mens SP., et al. “Eosinophilia in a solid tumor: ovarian sarcoma”. Dutch Timescher Healed 154 (2010).

Citation

Citation: Juan Gabriel Álvarez Sánchez and Ana Teresa Opina Pérez. “Phase I Diagnostic Study to Identify the Association Between Blood Eosinophilia and Ovarian Cancer Diagnosis". Acta Scientific Women's Health 5.2 (2023): 26-30.

Copyright

Copyright: © 2022 Juan Gabriel Álvarez Sánchez and Ana Teresa Opina Pérez. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.